We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oxford Pharm Gp | OXP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.50 | 1.50 |
| Top Posts |
|---|
Posted at 07/2/2017 11:02 by nick rubens It's a risk waiting for the a pull back IMO. Might get one, might not.At 2,6p, many likely thought i'll wait for a pullback and did they get one? hardly. Once the matket is confident it takes great courage to sell stock that looks set for a multibag and thats just to reach it's valuation placing that Professional investors funded it at, on the last round. If news comes and it's a major deal then even better. |
Posted at 17/1/2017 07:43 by timbo003 Here's the link to the proposed studies:Grasping at straws still I see Why don't they just give up on this stupid idea and either concentrate on their original core business of taste masking, or return cash to shareholders? Why on earth don't they realise that they cannot have their cake and eat it. Investors should not be seduced by the cash in the bank, as their approach to what they are trying to achieve is totally futile. |
Posted at 18/11/2016 13:30 by laptop15 Bounce time coming imo here guys....way too cheap! Big investors will want there returns at some stage and I'm sure they will get it! Just a matter of being patient and waiting for the news :) |
Posted at 03/11/2016 13:34 by laptop15 Hi guys, just bought in here as I heard there was plenty of value to be had due it being well funded and having very good investors :)) Also seems like plenty of upside potential as it seems to have been having a tough time with lots selling out. Sentiment is a strange this and it can change like the wind so here's to the wind changing now :))GLA |
Posted at 27/10/2016 11:31 by master rsi Large volume for the last few daysBelow is the last holdings list of investor's over 3% and in the absence of a change of major holdings RNS assume is still current, they could now be adding and the free float looks tiny. Woodford Investment Managers 401,597,920 33.31% Mr R Griffiths 173,071,097 14.35% David Norwood 105,938,633 8.79% Marcelo Bravo 65,000,000 5.39% Southern Fox Investments Ltd 51,000,000 4.23% Henderson Global Investors 49,400,000 4.10% Octopus Investments 42,140,345 3.50% Aviva Investors 37,964,329 3.15% Mr R Quested 37,247,753 3.09% |
Posted at 07/9/2016 16:38 by supernumerary The only large investors apart from the directors are Woodford and Griffiths, who own about 47% between them. You didn't lunch with either of them did you? |
Posted at 07/9/2016 15:52 by fillipe A good lunch and change of strategy!I still see nothing attractive here, except the cash pile - plus there must be some large investors who who are feeling more than a little of the cold dampness of the malcontent. A new broom and change of direction may be called for at OXP, in which case "better in than out" - hence I've taken a good number at a touch under the 3p, seemingly in common with other trades. Others will have their own reasons, but mine is a straight punt on changes being rung here and a resumption of at least the prospect of better things to come. On the other hand, no changes may well mean an end to my good lunches. gla f |
Posted at 07/9/2016 07:37 by timbo003 Interims out todayCash left at the end of June: £22m Market Cap: £37m Potential value of the so called "portfolio": very little The only thing they have which is of any value whatsoever is taste masking technology, the safer NSAID stuff is worth sweet fanny adams and the Safe stat is just a pipe dream. They should return the bulk of the cash back to shareholders and concentrate on the only thing of any value, i.e. taste masking. However, this isn't going to happen and go doubt there will be the usual band of hopelessly optimistic investors on LSE piling in as these speculative studies get underway later this year: Alongside these discussions, the Company has been advancing the technology, scaling-up and optimising the manufacturing process and strengthening its intellectual property (IP) portfolio. In the past six months, the Company has made significant progress in the laboratory, exploring and defining modifications of the OXPzero™ platform to affect release properties and enable bioequivalence/fast release of different formulations against different reference products. The Company has gained further understanding of the adaptable release properties of the technology and produced positive in vitro results that management believes bode well for in vivo performance. The Company will be conducting small scale exploratory pharmacokinetic (PK) clinical trials over several months starting later this year to validate the in vivo performance of these formulation improvements. Importantly, this is expected to generate new IP that will further strengthen the platform and provide longer patent life to the products once in market. |
Posted at 05/5/2016 15:22 by timbo003 Oxford Pharmascience will be presenting at the SHARES Investor Evening (London)on Wednesday 25th May 2016.I think I'll go along to that one. |
Posted at 02/5/2016 22:50 by timbo003 The slides and video from the Master Investor show are now available:OXP Slides: OXP Video: |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
